Lonza Won’t Compete With Partners In Teva Biosimilars Collaboration
This article was originally published in The Pink Sheet Daily
Swiss firm sees potential to earn $500 million to $750 million annually in follow-on biologics market.
You may also be interested in...
Israeli generic giant, Swiss CMO announce joint venture to co-develop, manufacture and market biosimilars.
Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.
Overall survival is more valid than freedom from progression in Phase III melanoma trial, firm says.